Antiepileptic Drug-Induced Neuronal Cell Death in the Immature Brain: Effects of Carbamazepine, Topiramate, and Levetiracetam as Monotherapy versus Polytherapy
- 16 July 2007
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 323 (1), 165-173
- https://doi.org/10.1124/jpet.107.126250
Abstract
The aim of this study was to test the potential neurotoxicity of three antiepileptic drugs (AEDs), carbamazepine (5H-dibenzepine-5-carboxamide), topiramate [2,3:4,5-bis-O-(1-methylethylidene)-beta-d-fructopyranose sulfamate], and levetiracetam [2-(2-oxopyrrolidin-1-yl)butanamide], in the developing rat brain, when given alone or in combinations. The extent of cell death induced by AEDs was measured in several brain regions of rat pups (postnatal day 8) by terminal deoxynucleotidyl transferase dUTP nick-end labeling assay 24 h after drug treatment. Carbamazepine alone did not increase neurodegeneration when given in doses up to 50 mg/kg, but it induced significant cell death at 100 mg/kg. When combined with phenytoin, carbamazepine, 50 but not 25 mg/kg, significantly exacerbated phenytoin-induced cell death. Although topiramate (20-80 mg/kg) alone caused no neurodegeneration, all doses exacerbated phenytoin-induced neurodegeneration. Levetiracetam (250-1000 mg/kg) alone did not induce cell death, nor did it exacerbate phenytoin-induced neurodegeneration. Of the combinations examined, only that of levetiracetam (250 mg/kg) with carbamazepine (50 mg/kg) did not induce neurodegeneration. Our data underscore the importance of evaluating the safety of combinations of AEDs given during development and not merely extrapolating from the effects of exposure to single drugs. Although carbamazepine and topiramate alone did not induce neuronal death, both drugs exacerbated phenytoin-induced cell death. In contrast, because cotreatment with levetiracetam and carbamazepine did not enhance cell death in the developing brain, it may be possible to avoid proapoptotic effects, even in polytherapy, by choosing appropriate drugs. The latter drugs, as monotherapy or in combination, may be promising candidates for the treatment of women during pregnancy and for preterm and neonatal infants.Keywords
This publication has 36 references indexed in Scilit:
- Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproateEpilepsy Research, 2007
- Common antiepileptic drugs in pregnancy in women with epilepsyPublished by Wiley ,2004
- Therapeutic doses of topiramate are not toxic to the developing rat brainExperimental Neurology, 2004
- Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsyEpilepsy Research, 2004
- Long‐term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonismEuropean Journal of Neuroscience, 2003
- Antiepileptic drugs and apoptotic neurodegeneration in the developing brainProceedings of the National Academy of Sciences, 2002
- Effect of topiramate following recurrent and prolonged seizures during early developmentEpilepsy Research, 2002
- Anticonvulsant Action of Topiramate Against Motor Seizures in Developing RatsEpilepsia, 2000
- Topiramate Pharmacokinetics in InfantsEpilepsia, 1999
- The non-competitive AMPA/kainate receptor antagonist, GYKI 52466, potentiates the anticonvulsant activity of conventional antiepilepticsEuropean Journal of Pharmacology, 1995